Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.

Retrovirology - 16 Feb 2016

Smith Steven J, Pauly Gary T, Akram Aamir, Melody Kevin, Rai Ganesha, Maloney David J, Ambrose Zandrea, Thomas Craig J, Schneider Joel T, Hughes Stephen H

Abstract excerpt

BACKGROUND: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 Å from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Research and Treatment
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV/AIDS drug development and treatment

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Rilpivirine

Source

Open in PubMed Open full text

Identifiers

PMID: 26880034
DOI: 10.1186/s12977-016-0244-2
PMCID: PMC4754833

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.PMID 26880034Read ↗

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.Semantic proximity Read ↗

Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.Semantic proximity Read ↗

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV InfectionSemantic proximity Read ↗

Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance developmentSemantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.Semantic proximity Read ↗

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.Semantic proximity Read ↗

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.Semantic proximity Read ↗

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.